The proposal addressed the need for novel monoclonal Abs (MAbs) to characterize subsets of immune cells and cytokines in the guinea pig model. The goal is to use their novel technology to produce high-affinity MAbs against six target antigens, focusing on surface markers of immune cells, and to characterize the specificity of antibodies with guinea pig PBMCs and tissue section. These new reagents will be available to significantly enhance research capabilities for tuberculosis and other diseases such as influenza, Ebola and Zika viral infections.